Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Date
2015Author
Solomon, Scott D.
Wu, Yujun
Pfeffer, Marc A.
Claggett, Brian
Diaz, Rafael
Dickstein, Kenneth
Gerstein, Hertzel C.
Johnston, Peter
Kober, Lars V.
Lawson, Francesca
Lewis, Eldrin F.
Maggioni, Aldo P.
McMurray, John J. V.
Ping, Lin
Probstfield, Jeffrey L.
Tardif, Jean-Claude
Bentley-Lewis, Rhonda
Aguilar, David
Riddle, Matthew C.
Metadata
Show full item recordAbstract
Background Cardiovascular (CV) disease is the leading cause of morbidity andmortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.
Collections
- Makale [92796]